Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis
Retrospective analysis shows that venetoclax improves overall remission and survival in AML-MR patients, highlighting its potential as a first-line therapy.
Key Points
VEN+HMA treatment achieved a significantly higher overall remission rate compared to priming regimens.
The overall survival for patients receiving VEN+HMA was significantly better than for those using priming regimens.
Multivariate analysis confirmed that VEN+HMA was an independent predictor of higher remission rates and survival.
These findings indicate that VEN+HMA may serve as a preferred low-intensity induction therapy for AML-MR.